TABLE 3.
Samples | Tissue | Age | DOC2B methylation | HPV status |
---|---|---|---|---|
% | ||||
N1 | Normal | 45 | 1.9 | N |
N2 | Normal | 50 | 7 | N |
N3 | Normal | 48 | 1.9 | N |
N4 | Normal | 42 | 1.9 | N |
N5 | Normal | 48 | 1.9 | N |
N6 | Normal | 55 | 1.7 | N |
Mean ± S.E. | 2.72 ± 0.86a | |||
P1 | LSIL | 40 | 25 | N |
P2 | LSIL | 46 | 42.85 | HPV16 |
P3 | LSIL | 46 | 26.92 | HPV16 |
P4 | LSIL | 54 | 13.46 | HPV18 |
P5 | HSIL | 53 | 19.23 | HPV16 |
P6 | HSIL | 74 | 11.53 | HPV11 |
Mean ± S.E. | 23.17 ± 4.66a | |||
T1 | PD-SCC (III-b) | 68 | 19.23 | N |
T2 | UD-SCC (II-b) | 71 | 30.76 | HPV18 |
T3 | LC-K-SCC (III-B) | 55 | 61.53 | HPV16 |
T4 | MD-SCC (II-b) | 52 | 19.23 | HPV16 |
T5 | LC-NK-SCC (I-b) | 40 | 1.9 | HPV16 |
T6 | LC-NK-SCC (I-a | 57 | 24.48 | HPV16 |
T7 | LC-NK-SCC (I-a) | 48 | 0 | N |
T8 | UD-SCC (II-b) | 55 | 17.3 | N |
T9 | PD-SCC (II-a) | 50 | 31.91 | HPV16 |
T10 | MD-SCC (III-b) | 40 | 30.76 | HPV18 |
T11 | MD-SCC (III-b) | 60 | 25 | HPV16 |
T12 | LC-NK-SCC (II-b) | 49 | 86.66 | HPV16 |
Mean ± S.E. | 29.06 ± 6.93a | |||
SiHa | 91.1 | HPV16 | ||
CaSki | 100 | HPV16 | ||
HeLa | 100 | HPV18 |
a According to one-way analysis of variance, the percentage of methylation was found to be statistically significant between normal and malignant samples. It was also found to statistically significant between normal and pre malignant and normal and malignant when Kruskal-Wallis test was performed. p value less than p < 0.05 was considered as statistically significant.